国元国际：创新药研发取得优异成果，建议积极关注歌礼制药（1672.HK）

权证网03-27

近日，国元国际发布歌礼制药研报，并建议积极关注。研报指出，公司创新药研发取得优异成果，现金储备充足。公司聚焦重点管线研发，包括痤疮/乙肝/NASH/脑胶质瘤/RSV多个疾病领域的6条II期或III期临床管线。其中ASC40（痤疮）已完成II期临床试验并达到主要及次要临床终点，III期临床试验入组中，ASC40治疗NASH患者的IIb期临床肝活检数据达到双终点，同时ASC40（脑胶质瘤）也已完成...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2422935387?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-27 13:34","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2422935387","market":"hk","top_or_hot":-1,"title":"国元国际：创新药研发取得优异成果，建议积极关注歌礼制药（1672.HK）","media":"权证网","content":"<div>\n<p>近日，国元国际发布歌礼制药研报，并建议积极关注。研报指出，公司创新药研发取得优异成果，现金储备充足。公司聚焦重点管线研发，包括痤疮/乙肝/NASH/脑胶质瘤/RSV多个疾病领域的6条II期或III期临床管线。其中ASC40（痤疮）已完成II期临床试验并达到主要及次要临床终点，III期临床试验入组中，ASC40治疗NASH患者的IIb期临床肝活检数据达到双终点，同时ASC40（脑胶质瘤）也已完成...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032713342787badc7b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国元国际：创新药研发取得优异成果，建议积极关注歌礼制药（1672.HK）</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国元国际：创新药研发取得优异成果，建议积极关注歌礼制药（1672.HK）\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-27 13:34 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032713342787badc7b&s=b><strong>权证网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，国元国际发布歌礼制药研报，并建议积极关注。研报指出，公司创新药研发取得优异成果，现金储备充足。公司聚焦重点管线研发，包括痤疮/乙肝/NASH/脑胶质瘤/RSV多个疾病领域的6条II期或III期临床管线。其中ASC40（痤疮）已完成II期临床试验并达到主要及次要临床终点，III期临床试验入组中，ASC40治疗NASH患者的IIb期临床肝活检数据达到双终点，同时ASC40（脑胶质瘤）也已完成...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032713342787badc7b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032713342787badc7b&s=b","article_id":"2422935387","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032713342787badc7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2422935387","pubTimestamp":1711517660,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，国元国际发布歌礼制药研报，并建议积极关注。研报指出，公司创新药研发取得优异成果，现金储备充足。ASC41NASH的II期期中分析数据12周治疗显著降低肝脂肪及炎症。国元国际认为，公司ASC40治疗痤疮，空间广阔。目前市值仅15亿港元，而且公司注重投资者回报，已经回购注销1.3亿港元股票，公司价值严重低估，建议积极关注。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","06978":"永泰生物-B","BK1161":"生物科技","BK1574":"生物医药B类股","01477":"欧康维视生物-B","01672":"歌礼制药-B","03323":"中国建材"},"translate_title":"Guoyuan International: Excellent achievements have been made in the research and development of innovative drugs. It is recommended to actively pay attention to Geli Pharmaceutical (1672. HK)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"01672":1,"06978":1,"03323":0.9},"content_text":"近日，国元国际发布歌礼制药研报，并建议积极关注。研报指出，公司创新药研发取得优异成果，现金储备充足。公司聚焦重点管线研发，包括痤疮/乙肝/NASH/脑胶质瘤/RSV多个疾病领域的6条II期或III期临床管线。其中ASC40（痤疮）已完成II期临床试验并达到主要及次要临床终点，III期临床试验入组中，ASC40治疗NASH患者的IIb期临床肝活检数据达到双终点，同时ASC40（脑胶质瘤）也已完成III期临床120患者入组。ASC22（PD-L1）在目前IIb拓展队列进展，50例患者完成入组，并发布期中数据。ASC41NASH的II期期中分析数据12周治疗显著降低肝脂肪及炎症。公司也将积极开拓国际BD项目合作，特别是ASC40（痤疮）项目，市场空间广阔。根据研报，公司2023年度收入增加4.6%至人民币5660万元，亏损大幅缩窄，主要由于产品销售收入增加；存货管理改善导致销售成本下降；以及其他收入及收益增加，主要由于银行利息收入及因SagimetBiosciences于二零二三年在纳斯达克股票市场首次公开发售产生的摊薄权益之收益。国元国际认为，公司ASC40治疗痤疮，空间广阔。ASC40的II期临床数据于23年5月公布：25毫克这一组总皮损减少了53.1%，50毫克这一组减少了61.3%，75毫克这一组，减少了53.1%，安慰剂减少了34.2%，疗效确切，有统计学意义。安全性良好。痤疮是全球第八大常见疾病，影响全球超过6.4亿人，目前缺乏合适的治疗药物，ASC40有望成为同类首创、每日一次、患者依从性高的口服痤疮药物。III期临床试验于23年12月启动，目前入组中，ASC40的市场空间广阔。国元国际指出，公司是创新研发驱动型生物科技公司，ASC40产品在痤疮/NASH/脑胶质瘤的管线研发上进展顺利，公司将围绕非酒精性脂肪肝炎、中重度痤疮、乙肝功能性治愈和新冠口服药，积极推进全球合作，公司现金储备22.75亿元，足够保障5年以上的研发投入需求。目前市值仅15亿港元，而且公司注重投资者回报，已经回购注销1.3亿港元股票，公司价值严重低估，建议积极关注。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422935387"}